Transgenomic is buying Clinical Data’s genetic and pharmacogenomic testing and biomarker development business for approximately $15.4 million. The transaction will allow Clinical Data to focus its resources solely on therapeutic development.
Archives for November 2010
Transgenomic Picks Up Clinical Data’s MDx and Biomarker Business for $15.4M
Quintiles, London Genetics Ally To Enhance Drug Discovery And Development Through Pharmacogenetics
Quintiles, the world’s leading bio pharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the bio pharmaceutical industry innovative pharmacogenetics solutions to advance personalized medicine. Financial terms were not disclosed.
Rosetta, Prometheus Settle Arbitration on MicroRNA Tests
Rosetta Genomics today said that it has settled an outstanding arbitration with Prometheurs Laboratories regarding commercialization rights to Rosetta’s microRNA-based tests.
Under the terms of the settlement, Rosetta has regained US commercial rights to its miRview mets, miRview squamous, and miRview meso tests. The Rehovot, Israel-based firm will pay Prometheus $3.1 million over the next 18 months, with an initial payment of $1.2 million due on Dec. 2.
MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences
MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has agreed to out-license certain DNA methylation biomarkers to Predictive Biosciences (Lexington, MA) for diagnostic applications in bladder cancer.